GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hunan Er-Kang Pharmaceutical Co Ltd (SZSE:300267) » Definitions » 3-Year EPS without NRI Growth Rate

Hunan Er-Kang Pharmaceutical Co (SZSE:300267) 3-Year EPS without NRI Growth Rate : 0.00% (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Hunan Er-Kang Pharmaceutical Co 3-Year EPS without NRI Growth Rate?

Hunan Er-Kang Pharmaceutical Co's EPS without NRI for the three months ended in Mar. 2024 was ¥0.00.

During the past 12 months, Hunan Er-Kang Pharmaceutical Co's average EPS without NRI Growth Rate was -330.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Hunan Er-Kang Pharmaceutical Co was 97.60% per year. The lowest was -47.00% per year. And the median was 28.10% per year.


Competitive Comparison of Hunan Er-Kang Pharmaceutical Co's 3-Year EPS without NRI Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Hunan Er-Kang Pharmaceutical Co's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hunan Er-Kang Pharmaceutical Co's 3-Year EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hunan Er-Kang Pharmaceutical Co's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Hunan Er-Kang Pharmaceutical Co's 3-Year EPS without NRI Growth Rate falls into.



Hunan Er-Kang Pharmaceutical Co 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Hunan Er-Kang Pharmaceutical Co  (SZSE:300267) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Hunan Er-Kang Pharmaceutical Co 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Hunan Er-Kang Pharmaceutical Co's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Business Description

Traded in Other Exchanges
N/A
Address
Kangping Road 167, National Economic and Technological Development Zone, Liuyang Changsha, Hunan, CHN, 410331
Hunan Er-Kang Pharmaceutical Co Ltd develops, produces and sells pharmaceutical products in China. The company's main products include pharmaceutical excipients and antibiotics. It offers pharmaceutical excipients, APIs and finished drug products. The pharmaceutical excipients include products such as glycerol, ethanol pharmaceutically, acceptable propylene glycol, sodium hydroxide, and pharmaceutically acceptable sugar. The company's finished drugs primarily include sulbenicillin sodium for injection and compound liquorice tablets. Its APIs include glycerin, dilute hydrochloric acid, dihydroxypropyl theophylline, sulbenicillin sodium, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. Geographically, all the activities are carried out through China.

Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Headlines

No Headlines